Literature DB >> 3538563

Analysis of pharmacokinetic profiles in 232 renal and 87 cardiac allograft recipients treated with cyclosporine.

B D Kahan, W G Kramer, C A Wideman, O H Frazier, M I Lorber, C Williams, S M Flechner, D A Cooley, C T Van Buren.   

Abstract

Analyses of cyclosporine (CsA)-related compounds (Cs) using the radioimmunoassay method were performed by 232 profiles in renal and 87 profiles in cardiac allograft recipients. Cardiac allograft recipients tended to have an increased, dose-corrected area under the concentration (AUC) v time curves after oral and, particularly, intravenous CsA administration, to display a slower drug clearance rate, and to have a slightly smaller volume of distribution. The impact of age, sex, hepatic impairment, nephrotoxicity, and concomitant corticosteroid dose could be discerned within the large number of studies in renal recipients. Only nephrotoxic cardiac transplant patients showed a significant alteration of increased AUC:dose and drug half-life compared with patients with normal renal function, a similar change to that observed in nephrotoxic renal transplant patients. Pediatric compared with adult renal recipients showed a threefold increased rate of mean drug clearance, namely 39.6 mL/min/kg in children v 12.3 mL/min/kg in adults, which may explain the almost 50% reduction in area under the plasma concentration curve v the time curve. There also appeared to be somewhat better oral absorption of CsA by children. Study of greater numbers of cardiac transplant recipients will be necessary to detect the subtle impact of demographic factors on pharmacokinetic parameters.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3538563

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  8 in total

Review 1.  The use of therapeutic drug monitoring to optimise immunosuppressive therapy.

Authors:  S M Tsunoda; F T Aweeka
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

Review 2.  How important are gender differences in pharmacokinetics?

Authors:  Bernd Meibohm; Ingrid Beierle; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 3.  Methods for clinical monitoring of cyclosporin in transplant patients.

Authors:  R J Dumont; M H Ensom
Journal:  Clin Pharmacokinet       Date:  2000-05       Impact factor: 6.447

Review 4.  Switching between cyclosporin formulations. What are the risks?

Authors:  A J Olyaei; A M deMattos; W M Bennett
Journal:  Drug Saf       Date:  1997-06       Impact factor: 5.606

5.  Evidence for pre-hepatic metabolism of oral cyclosporine in children.

Authors:  K Hoppu; O Koskimies; C Holmberg; E L Hirvisalo
Journal:  Br J Clin Pharmacol       Date:  1991-10       Impact factor: 4.335

6.  Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients.

Authors:  Dirk R J Kuypers; Kathleen Claes; Pieter Evenepoel; Bart Maes; Willy Coosemans; Jacques Pirenne; Yves Vanrenterghem
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 7.  Clinical pharmacokinetics in organ transplant patients.

Authors:  R Venkataramanan; K Habucky; G J Burckart; R J Ptachcinski
Journal:  Clin Pharmacokinet       Date:  1989-03       Impact factor: 6.447

Review 8.  Therapeutic drug monitoring of cyclosporin. Practical applications and limitations.

Authors:  V Rodighiero
Journal:  Clin Pharmacokinet       Date:  1989-01       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.